Replies to post #125644 on Anavex Life Sciences Corp (AVXL)

[Batermere]

Don't mess with Zena. She knows her stuff. This is an ANAVEX MB, BTW.

[Mikesc]

You Go GIRL!

[XenaLives]

Sorry, I was so ticked off that I forgot to link to the source of my quotes.

http://www.alzforum.org/therapeutics/azeliragon

[powerwalker]

Actually, Xena, it will be three years this December/January, not two.

[F1ash]

Lack of relevance per safety issues - some people have been on 2-73 for close to two years now.

You make a good point. I see now that the high dose of the other drug was only tested for 10 weeks in the first trial and didn’t develop safety issues until 6 months in the second trial. I don’t believe we know what dose the dropouts were on with Anavex (do we?) so perhaps it is indeed a nonissue since ~9 people have apparently been able to tolerate 50mg of A2-73 for over a year.

Probably wouldn’t have been a deal breaker anyway imho, because they have 20mg to play with between the 30mg and 50mg dose. (Could just try 40 mg if necessary for example)

That post was 100% obfuscation.

Complete lack of correlation and misrepresentation of data...

Different MOA

Really because I said this:




2. Who would have guessed the FDA would grant “fast track” as results didn’t seem particularly impressive. Perhaps a good sign for A2-73’s chances.

3. Notice how long the trial is taking even with Fast Track? Three years! And that’s for strictly a Phase 3 not a combined 2/3. They actually received fast track in 2013 so it’s been closer to 5 years to design and complete the Phase 3.


4. Perhaps “rates of hippocampal shrinking or CSF biomarker measures. “ are indicators that Anavex should be measuring?

5. Looks like this soon to be completed trial is not targeting A-beta either, maybe it can help lower that 99.6 rate?


Which one of those didn’t you like. (I was shocked at how long it still took with Fast-track status myself but please don’t shoot the messenger. Hippocampal shrinkage is an interesting metric what would be wrong with Anavex utilizing that measure?



Now I have an important question for you!


Do you believe the 99.6% failure rate for Alzheimer’s trials doesn’t apply to Anavex because A2-73 is targeting Sigma 1 and not A-beta and Plaques?